At present, we therefore interpret prior -lactam allergy as a potential marker of immunologic susceptibility rather than a proven independent risk factor
Clinicians utilizing these findings have developed targeted treatment protocols, often referred to as the "Brewer Protocol," which focus on eradicating fungal colonization in the sinus cavities using biofilm disruptors and intranasal antifungals
Read on to discover the potential of this powerful duo
Addressing Current Gaps and Unmet Needs GLP-1R agonists have rapidly evolved from glucose-lowering agents for T2DM to multifaceted therapeutics with FDA- and EMA-approved indications for obesity, cardiovascular disease, chronic kidney disease, diabetic nephropathy, and sleep apnea
Furthermore, ROS formation was significantly increased in models treated with 10 M and 20 M TVX compared to LVX at equal concentrations